Tesamorelin

99%+ Purity USA Tested

Research Use Only. Not for Human or Veterinary Use

Tesamorelin: GHRH analog peptide, CAS 218949-48-5, MW 5135.90 g/mol, ≥99% purity. Lyophilized powder for laboratory use.

$80.00

Out of stock

Peptide Name	Tesamorelin (TH-9507)
CAS Number	218949-48-5
Molecular Formula	C₂₂₁H₃₆₆N₇₂O₆₇S₁
Molecular Weight	5135.90 g/mol
Mechanism Class	GHRH analog
Appearance	White lyophilized powder
Purity	≥99% (HPLC)
Storage	-20°C, desiccated, protected from light
Solubility	Soluble in sterile water

This product is not intended for human or animal use. For scientific research only.

VivePeptides provides detailed analytical results including High-Performance Liquid Chromatography (HPLC) and mass spectrometry data for all peptides. These reports confirm peptide purity, composition, and molecular accuracy, giving researchers full transparency and confidence in the materials used for their studies.

VIEW COA

VivePeptides peptides should be stored in a cool, dry environment and protected from light and moisture. Lyophilized peptides are best kept refrigerated or frozen until use to maintain stability. Once reconstituted for research purposes, peptides should be stored according to standard laboratory protocols, typically under refrigeration, and handled using proper aseptic techniques to preserve integrity throughout the study period.

OVERVIEW

What Is Tesamorelin Peptide?

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), consisting of the full 44-amino acid GHRH sequence modified with a trans-3-hexenoic acid group attached to the tyrosine residue at position 1. This modification enhances the peptide’s stability while preserving its ability to interact with GHRH receptors. As a tesamorelin GHRH analog, it represents one of the most well-characterized compounds in growth hormone axis research.

Tesamorelin peptide was originally developed by Theratechnologies and has been the subject of extensive preclinical and research investigation. Tesamorelin growth hormone research has documented its ability to stimulate pituitary somatotroph cells through GHRH receptor activation, leading to pulsatile growth hormone secretion in research models. The peptide’s defined mechanism and well-characterized pharmacology make it a valuable research tool for studying the somatotropic axis, GH-IGF-1 signaling, and related metabolic pathways in laboratory settings.

GHRH Analog

Modified 44-amino acid growth hormone-releasing hormone peptide

≥99% HPLC Purity

Every batch verified via high-performance liquid chromatography

USA Tested & Verified

Third-party analytical testing performed in USA laboratories

RESEARCH

Tesamorelin Mechanism of Action in Research

The tesamorelin mechanism of action follows the classical GHRH signaling pathway while offering enhanced stability over native GHRH. Tesamorelin research has characterized its receptor pharmacology and downstream effects on the somatotropic axis.

GHRH Receptor Activation

Tesamorelin binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor expressed on anterior pituitary somatotroph cells. Upon receptor binding, tesamorelin activates the Gs-adenylyl cyclase-cAMP-PKA signaling cascade, leading to calcium influx and growth hormone (GH) release from secretory granules. Published tesamorelin research demonstrates that the trans-3-hexenoic acid modification does not significantly alter receptor binding affinity compared to native GHRH, while providing improved metabolic stability.

Pulsatile Growth Hormone Secretion

A key feature of the tesamorelin mechanism of action is its promotion of physiological pulsatile GH secretion rather than continuous elevation. Tesamorelin growth hormone research has shown that GHRH receptor activation produces GH release patterns that follow natural secretory dynamics, preserving the normal feedback mechanisms of the somatotropic axis. This distinguishes GHRH analogs from direct GH administration in research contexts.

IGF-1 Axis and Downstream Signaling

Tesamorelin research has documented downstream effects on the insulin-like growth factor-1 (IGF-1) axis. By stimulating GH release, tesamorelin indirectly influences hepatic IGF-1 production and the GH-IGF-1 signaling cascade, providing researchers with a tool to study the full somatotropic axis from hypothalamic input through peripheral effector pathways. —

COMPARISON

Tesamorelin vs Sermorelin: GHRH Analog Research Comparison

Tesamorelin and sermorelin are both GHRH analogs used in growth hormone research, but they differ in length, modification strategy, and pharmacological profiles.

Feature	Tesamorelin	Sermorelin
Structure	Modified GHRH(1-44)-NH₂	GHRH(1-29)-NH₂
CAS Number	218949-48-5	86168-78-7
Amino Acids	44	29
Molecular Weight	5135.89 Da	3357.88 Da
Modification	Trans-3-hexenoic acid at Tyr1	None (truncated native sequence)
Receptor Target	GHRH-R	GHRH-R
Full GHRH Sequence	Yes (complete 1-44)	Partial (1-29, minimal active fragment)
Research Documentation	Extensively published	Well-established research tool

Both tesamorelin and sermorelin activate the GHRH receptor, but tesamorelin contains the complete GHRH(1-44) sequence with an additional stability modification. Researchers can buy tesamorelin from VivePeptides at ≥99% purity for growth hormone axis research.

RESEARCH STUDIES

Tesamorelin Research Applications & Published Studies

Tesamorelin research spans a substantial body of published literature examining its effects on growth hormone secretion and related metabolic pathways.

Growth Hormone Secretion Studies

Published tesamorelin growth hormone research has documented its effects on GH secretion dynamics in multiple experimental models. Studies have characterized the dose-response relationship of tesamorelin-stimulated GH release, its effects on GH pulse amplitude and frequency, and its interactions with somatostatin-mediated inhibitory feedback. These studies establish tesamorelin as a reliable tool for GHRH receptor pharmacology research.

Lipid Metabolism and Body Composition Research

Tesamorelin research has included investigations of GH-mediated effects on lipid metabolism. Published studies have documented changes in visceral adipose tissue, hepatic fat content, and lipid profiles in animal models following GHRH receptor activation. Falutz et al. (New England Journal of Medicine, 2007) published pivotal research characterizing tesamorelin’s effects on trunk fat parameters, contributing to our understanding of GH-mediated lipid metabolism.

Hepatic and Metabolic Pathway Studies

Additional tesamorelin research has explored its effects on hepatic function and metabolic parameters. Studies have examined tesamorelin’s influence on liver fat content, insulin sensitivity markers, and lipid oxidation pathways. Stanley et al. (Lancet HIV, 2019) published findings on tesamorelin’s effects in research models examining hepatic steatosis parameters, expanding the scope of GHRH analog research.

QUALITY ASSURANCE

Quality & Testing Standards

HPLC & Mass Spectrometry

Every tesamorelin batch undergoes HPLC and mass spectrometry analysis to confirm identity, purity, and molecular weight.

Third-Party Verified

All tesamorelin is independently tested at third-party USA-based analytical laboratories.

≥99% Purity Standard

VivePeptides tesamorelin consistently meets or exceeds ≥99% purity for reliable growth hormone research.

FAQ

Frequently Asked Questions About Tesamorelin

What is tesamorelin used for in research?

Tesamorelin is used in preclinical research to study GHRH receptor signaling, pulsatile growth hormone secretion, the GH-IGF-1 axis, and related metabolic pathways. Tesamorelin is sold for research use only.

What purity is VivePeptides tesamorelin?

VivePeptides tesamorelin peptide is manufactured to ≥99% purity as verified by HPLC. Each batch undergoes independent testing at USA-based analytical laboratories.

How should tesamorelin be stored?

Lyophilized tesamorelin should be stored at -20°C, protected from light and moisture. Reconstituted solutions should be stored at 2–8°C and used within 7 days.

What is the trans-3-hexenoic acid modification in tesamorelin?

The trans-3-hexenoic acid moiety is covalently attached to the N-terminal tyrosine residue of the GHRH(1-44) sequence. This modification enhances the peptide’s stability against enzymatic degradation without significantly altering its GHRH receptor binding affinity, resulting in a more stable research compound compared to native GHRH.

Is VivePeptides tesamorelin third-party tested?

Yes. Every lot of VivePeptides tesamorelin undergoes independent third-party testing at USA-based laboratories, including HPLC and mass spectrometry analysis. Test results are available upon request for qualified researchers.

Related Research Peptides

Explore other research-grade peptides available from VivePeptides. Each product meets the same rigorous purity and testing standards.

CJC-1295 No DAC + Ipamorelin

Growth hormone secretagogue research blend

MOTS-c

Mitochondrial-derived peptide for metabolic research

Semaglutide

GLP-1 receptor agonist for metabolic pathway research

BPC-157

Gastric pentadecapeptide for tissue biology research

Explore More Research Peptides

All Peptides → · Tirzepatide · Retatrutide · NAD+ · GHK-Cu · Selank · Semax · BAC Water